{
    "text_blocks": {
        "data": {
            "block_count": 1,
            "table_index": 0
        },
        "model": null,
        "timestamp": "2025-01-21_09-31-22"
    },
    "table_comments": {
        "data": "CONSOLIDATED BALANCE SHEETS\tDollars in Millions\t(UNAUDITED)\t",
        "timestamp": "2025-03-11_12-12-11"
    },
    "units": {
        "data": {
            "sum_units": 1000000,
            "sum_divider": 1.0
        },
        "model": {
            "gpt-4o-mini-2024-07-18": {
                "votes": {
                    "0": "1000000",
                    "1": "1000000"
                },
                "decision": "1000000"
            },
            "gpt-4o-2024-08-06": {
                "votes": null,
                "decision": null
            }
        },
        "timestamp": "2025-03-11_12-12-14"
    },
    "post_table_text": {
        "data": "\tThe accompanying notes are an integral part of these consolidated financial statements.\t4\tBRISTOL-MY",
        "model": {
            "gpt-4o-mini-2024-07-18": {
                "trials": {
                    "0": "'\t\tThe accompanying notes are an integral part of these consolidated financial statements.\t4\tBR'",
                    "1": "'\tThe accompanying notes are an integral part of these consolidated financial statements.\t4\tBRISTOL-MY'"
                },
                "decision": "'\tThe accompanying notes are an integral part of these consolidated financial statements.\t4\tBRISTOL-MY'"
            },
            "gpt-4o-2024-08-06": {
                "trials": {},
                "decision": null
            }
        },
        "timestamp": "2025-03-11_12-12-18"
    },
    "table_body": {
        "data": "ASSETS\tJune 30,\t2020\tDecember 31,\t2019\tCurrent Assets:\tCash and cash equivalents\t$\t19,934\t$\t12,346\tMarketable debt securities\t1,724\t3,047\tReceivables\t7,855\t7,685\tInventories\t2,384\t4,293\tOther current assets\t2,446\t1,983\tTotal Current Assets\t34,343\t29,354\tProperty, plant and equipment\t5,777\t6,252\tGoodwill\t20,578\t22,488\tOther intangible assets\t59,171\t63,969\tDeferred income taxes\t1,088\t510\tMarketable debt securities\t523\t767\tOther non-current assets\t6,596\t6,604\tTotal Assets\t$\t128,076\t$\t129,944\tLIABILITIES\tCurrent Liabilities:\tShort-term debt obligations\t$\t4,819\t$\t3,346\tAccounts payable\t2,852\t2,445\tOther current liabilities\t15,750\t12,513\tTotal Current Liabilities\t23,421\t18,304\tDeferred income taxes\t6,157\t6,454\tLong-term debt\t41,853\t43,387\tOther non-current liabilities\t7,485\t10,101\tTotal Liabilities\t78,916\t78,246\tCommitments and contingencies\tEQUITY\tBristol-Myers Squibb Company Shareholders  Equity:\tPreferred stock\t \t \tCommon stock\t292\t292\tCapital in excess of par value of stock\t44,444\t43,709\tAccumulated other comprehensive loss\t(\t1,556\t)\t(\t1,520\t)\tRetained earnings\t31,565\t34,474\tLess cost of treasury stock\t(\t25,651\t)\t(\t25,357\t)\tTotal Bristol-Myers Squibb Company Shareholders  Equity\t49,094\t51,598\tNoncontrolling interest\t66\t100\tTotal Equity\t49,160\t51,698\tTotal Liabilities and Equity\t$\t128,076\t$\t129,944",
        "timestamp": "2025-03-11_12-12-18"
    },
    "table_json_created": {
        "data": true,
        "model": {
            "gpt-4o-mini-2024-07-18": {
                "trials": {
                    "0": "{\"ASSETS\": {\"Current Assets\": {\"Cash and cash equivalents\": [19934, 12346], \"Marketable debt securities\": [1724, 3047], \"Receivables\": [7855, 7685], \"Inventories\": [2384, 4293], \"Other current assets\": [2446, 1983], \"Total Current Assets\": [34343, 29354]}, \"Property, plant and equipment\": [5777, 6252], \"Goodwill\": [20578, 22488], \"Other intangible assets\": [59171, 63969], \"Deferred income taxes\": [1088, 510], \"Marketable debt securities\": [523, 767], \"Other non-current assets\": [6596, 6604], \"Total Assets\": [128076, 129944]}, \"LIABILITIES\": {\"Current Liabilities\": {\"Short-term debt obligations\": [4819, 3346], \"Accounts payable\": [2852, 2445], \"Other current liabilities\": [15750, 12513], \"Total Current Liabilities\": [23421, 18304]}, \"Deferred income taxes\": [6157, 6454], \"Long-term debt\": [41853, 43387], \"Other non-current liabilities\": [7485, 10101], \"Total Liabilities\": [78916, 78246], \"Commitments and contingencies\": null}, \"EQUITY\": {\"Bristol-Myers Squibb Company Shareholders Equity\": {\"Preferred stock\": [0, 0], \"Common stock\": [292, 292], \"Capital in excess of par value of stock\": [44444, 43709], \"Accumulated other comprehensive loss\": [-1556, -1520], \"Retained earnings\": [31565, 34474], \"Less cost of treasury stock\": [-25651, -25357], \"Total Bristol-Myers Squibb Company Shareholders Equity\": [49094, 51598]}, \"Noncontrolling interest\": [66, 100], \"Total Equity\": [49160, 51698]}, \"Total Liabilities and Equity\": [128076, 129944]}"
                },
                "decision": "{\"ASSETS\": {\"Current Assets\": {\"Cash and cash equivalents\": [19934, 12346], \"Marketable debt securities\": [1724, 3047], \"Receivables\": [7855, 7685], \"Inventories\": [2384, 4293], \"Other current assets\": [2446, 1983], \"Total Current Assets\": [34343, 29354]}, \"Property, plant and equipment\": [5777, 6252], \"Goodwill\": [20578, 22488], \"Other intangible assets\": [59171, 63969], \"Deferred income taxes\": [1088, 510], \"Marketable debt securities\": [523, 767], \"Other non-current assets\": [6596, 6604], \"Total Assets\": [128076, 129944]}, \"LIABILITIES\": {\"Current Liabilities\": {\"Short-term debt obligations\": [4819, 3346], \"Accounts payable\": [2852, 2445], \"Other current liabilities\": [15750, 12513], \"Total Current Liabilities\": [23421, 18304]}, \"Deferred income taxes\": [6157, 6454], \"Long-term debt\": [41853, 43387], \"Other non-current liabilities\": [7485, 10101], \"Total Liabilities\": [78916, 78246], \"Commitments and contingencies\": null}, \"EQUITY\": {\"Bristol-Myers Squibb Company Shareholders Equity\": {\"Preferred stock\": [0, 0], \"Common stock\": [292, 292], \"Capital in excess of par value of stock\": [44444, 43709], \"Accumulated other comprehensive loss\": [-1556, -1520], \"Retained earnings\": [31565, 34474], \"Less cost of treasury stock\": [-25651, -25357], \"Total Bristol-Myers Squibb Company Shareholders Equity\": [49094, 51598]}, \"Noncontrolling interest\": [66, 100], \"Total Equity\": [49160, 51698]}, \"Total Liabilities and Equity\": [128076, 129944]}"
            },
            "gpt-4o-2024-08-06": {
                "trials": {},
                "decision": null
            }
        },
        "timestamp": "2025-03-12_11-20-32"
    },
    "problems": {
        "data": [],
        "timestamp": "2025-03-12_11-20-32"
    }
}